These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15918336)

  • 1. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.
    Ray AS; Myrick F; Vela JE; Olson LY; Eisenberg EJ; Borroto-Esodo K; Miller MD; Fridland A
    Antivir Ther; 2005; 10(3):451-7. PubMed ID: 15918336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.
    Borroto-Esoda K; Vela JE; Myrick F; Ray AS; Miller MD
    Antivir Ther; 2006; 11(3):377-84. PubMed ID: 16759055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir.
    Kulkarni R; Feng JY; Miller MD; White KL
    Antiviral Res; 2014 Jan; 101():131-5. PubMed ID: 24291780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
    Hawkins T; Veikley W; St Claire RL; Guyer B; Clark N; Kearney BP
    J Acquir Immune Defic Syndr; 2005 Aug; 39(4):406-11. PubMed ID: 16010161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
    Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
    Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors.
    Venhoff N; Setzer B; Melkaoui K; Walker UA
    Antivir Ther; 2007; 12(7):1075-85. PubMed ID: 18018766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir.
    Hossain MM; Coull JJ; Drusano GL; Margolis DM
    Antiviral Res; 2002 Jul; 55(1):41-52. PubMed ID: 12076750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
    Stone C; Ait-Khaled M; Craig C; Griffin P; Tisdale M
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1413-5. PubMed ID: 15047556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
    Curran A; Martinez E; Podzamczer D; Lonca M; Barragan P; Crespo M; Falco V; Vidal-Sicart S; Imaz A; Martinez M; Gatell JM; Ribera E
    Antivir Ther; 2012; 17(4):711-8. PubMed ID: 22374987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1.
    Lanier ER; Hazen R; Ross L; Freeman A; Harvey R
    J Acquir Immune Defic Syndr; 2005 Aug; 39(5):519-22. PubMed ID: 16044001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
    Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.
    Feng JY; Ly JK; Myrick F; Goodman D; White KL; Svarovskaia ES; Borroto-Esoda K; Miller MD
    Retrovirology; 2009 May; 6():44. PubMed ID: 19439089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human leukocyte recruitment.
    De Pablo C; Orden S; Calatayud S; Martí-Cabrera M; Esplugues JV; Alvarez A
    Antivir Ther; 2012; 17(8):1615-9. PubMed ID: 22954798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.
    Goicoechea M; Jain S; Bi L; Kemper C; Daar ES; Diamond C; Ha B; Flaherty J; Sun S; Richman D; Louie S; Haubrich R;
    AIDS; 2010 Mar; 24(5):707-16. PubMed ID: 20087154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
    Callebaut C; Stepan G; Tian Y; Miller MD
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.
    Hernandez-Santiago BI; Mathew JS; Rapp KL; Grier JP; Schinazi RF
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2130-5. PubMed ID: 17403996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
    Balestre E; Dupon M; Capdepont S; Thiébaut R; Boucher S; Fleury H; Dabis F; Masquelier B;
    J Clin Virol; 2006 Jun; 36(2):95-9. PubMed ID: 16556509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.